Nutra Pharma is announcing the launch of their new homeopathic formula for the treatment of chronic pain in companion animals, Pet Pain-Away.
June 24, 2013 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they are in the process of launching the newest addition to their line of homeopathic treatments for chronic pain, Pet Pain-Away.
Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs, cats and horses. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.
“Most of the pain-relieving drugs currently available for both the human and animal markets have severe side effects that may include gastrointestinal difficulties, kidney issues and narcotic problem,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "Pet Pain-Away is a revolutionary new product that promises to change the way we deal with pet pain. It is the culmination of years of scientific research coupled with proven ancient Chinese medicine and homeopathic practices to produce a single sensible solution to pain in pets," he continued. "We also know that Americans are apt to spend more on their pets than themselves, especially in indications of comfort and pain," he concluded.
According to The Humane Society there are 75 million dog owners and 85 million cat owners in the US. These companion animals are as susceptible as humans to ailments that require pain-relieving solutions. The total market for companion animals in the US reached an estimated $47.7 billion in 2010, up from $28.5 billion in 2001 (up 167%). Of these expenditures, over $11 billion was spent on medication for the animals. Additionally, a 2009 survey conducted by Virbac Pharmaceuticals puts the annual US market for companion animal pain relievers at more than $250 million.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The launch of Pet Pain-Away should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.